Alpha-glucosidase inhibitors in clinical practice. Questions and answers

Main Article Content

L.K. Sokolova


The article deals with the use of a class of alpha-glucosidase inhibitors in patients with diabetes mellitus.

Article Details

How to Cite
Sokolova, L. “Alpha-Glucosidase Inhibitors in Clinical Practice. Questions and Answers”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 1, Mar. 2018, pp. 71-75, doi:10.22141/2224-0721.14.1.2018.127096.
To practicing Endocrinologists


Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072-7. doi: 10.1016/S0140-6736(02)08905-5.

Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:25-30. doi: 10.4158/EP.12.S1.25.

Pasiechko NV, Loy NYa, Mazur LP, Savchenko IP. The efficiency of using α-glucosidase inhibitors in patients with diabetes mellitus type 2 and obesity. Mìžnarodnij endokrinologìčnij žurnal. 2015;2(66):75-78. doi: 10.22141/2224-0721.2.66.2015.75444. (in Ukrainian).

Pasiechko NV, Naumova LV, Skrypnyk NV, Svystun II, Golyk IV. The efficiency of using Siofor in patients with obesity and hyperinsulinism on the stage of prediabetes. Mìžnarodnij endokrinologìčnij žurnal. 2012;2(42):83-86. (in Ukrainian).

Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607-14. doi: 10.1016/S0140-6736(09)60222-1.

Cherniavska IV. Profile of cardiovascular risk factors in ischemic heart disease in patients with normal and impaired carbohydrate metabolism. Mìžnarodnij endokrinologìčnij žurnal. 2016;3(75):27-31. doi: 10.22141/2224-0721.3.75.2016.76627. (in Ukrainian).

Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28(1):154-163. PMID: 15616251.

Holman RR. Acarbose Cardiovasular Evaluation (ACE): primary results. In: Proceeding of the 53rd Annual Meeting of the European Association for the Study of Diabetes. 2017 Sep 11-15; Lisbon, Portugal.

Pankiv VI. Impact of voglibose on metabolic control indicators in patients with diabetes mellitus type 1. Mìžnarodnij endokrinologìčnij žurnal. 2015;1(65):33-7. doi: 10.22141/2224-0721.1.65.2015.75889. (in Ukrainian).

Pankiv VI. Preventive and therapeutic effect of voglibose in management of diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2014;5(61):83-87. doi: 10.22141/2224-0721.5.61.2014.76860. (in Ukrainian).

Pankiv VI. New therapeutic possibilities of type 2 diabetes mellitus management: experience of voglibose application. Mìžnarodnij endokrinologìčnij žurnal. 2014;6(62):51-54. doi: 10.22141/2224-0721.6.62.2014.76937. (in Ukrainian).

Pankiv VI, Cherniavska IV. Choice of method for type 2 diabetes mellitus prevention: as pathogenetic approach using voglibose. Mìžnarodnij endokrinologìčnij žurnal. 2014;7(63):45-49. doi: 10.22141/2224-0721.7.63.2014.77127. (in Ukrainian).

Pankiv VI. Inhibitor of α-glucosidase voglibose: new possibilities of treatment and prevention of diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2013;7(55):35-38. doi: 10.22141/2224-0721.7.55.2013.84676 (in Ukrainian).

Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care. 2017 Jan;40(Suppl 1):S4-S5. doi: 10.2337/dc17-S003.

International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014 Apr;104(1):1-52. doi: 10.1016/j.diabres.2012.10.001.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS.

Most read articles by the same author(s)